Development of a Biosimilar of Agalsidase Beta for the Treatment of Fabry Disease: Preclinical Evaluation.

André B P van KuilenburgCarla E M HollakAna TravellaMelisa JacobsLucas D GentiliniRené LeenKaren M M Ghauharali-van der VlugtFemke S Beers StetSusan M I GoordenSanne van der VeenMarcelo CriscuoloMariana Papouchado

Published in: Drugs in R&D (2023)

These findings support the biosimilarity of AGABIO in comparison with agalsidase beta. The clinical study phase is currently under development.

Keyphrases

replacement therapy
stem cells
cell therapy
combination therapy